BioSpace News Archive

Daiichi Sankyo Company, Limited and AstraZeneca’s ENHERTU® has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

Jianshun Biosciences Co., Ltd. recently announced its strategic partnership with Etta Biotech Co., Ltd., to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, reported a full analysis of the final data, including mature overall survival results, from its global Phase 3 ClarIDHy trial of TIBSOVO® in patients with previously treated isocitrate dehydrogenase 1 mutated cholangiocarcinoma.

Mitsubishi Electric Corporation and Tokyo Institute of Technology announced their joint development of an original blockchain technology that can optimize peer-to-peer energy trading.

Senseonics Holdings, Inc. announced that it has entered into securities purchase agreements with several healthcare-focused and other institutional investors to purchase 40,000,000 shares of its common stock in a registered direct offering at a purchase price of $1.25 per share.

As the resurgence of COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians, public health, laboratory and healthcare capacity.

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced dose administration for the first patient in a Phase 2a clinical study of the company’s lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma.